SEC Form 4 · accession 0001193125-26-398204
4D Molecular Therapeutics, Inc. · FDMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Bizily
Officer — Chief Legal Officer
Period of report
Sep 16, 2026
Accepted (ET)
Sep 22, 2026 · 6:43 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 16, 2026 | M | 1,635 | $4.14 | A | 10,252 | D | |
| Common Stock | Sep 16, 2026 | S | 1,635 | $13.65 | D | 8,617 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.14 | Sep 16, 2026 | M | 1,635 | D | — | Mar 5, 2035 | Common Stock | 1,635 | 58,066 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
- F2The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.